The abstract is read at the publisher; the summary is JClub's.
Vutrisiran’s effect on all-cause mortality and recurrent cardiovascular events in HELIOS-B ATTR-CM is directionally consistent regardless of baseline tafamidis use, with rate ratios 0.79 vs 0.67.
- Why it matters: Clinicians need evidence on whether adding vutrisiran to baseline transthyretin stabilization changes outcomes, but prior combination data are limited.
- What they did: In HELIOS-B, 654 randomized patients received vutrisiran 25 mg or placebo every 3 months for up to 36 months, with tafamidis permitted and stratified; outcomes included mortality, cardiovascular events, 6-minute walk distance, and KCCQ-OSS.
- The result: No statistically significant interaction by baseline tafamidis was found for the primary outcome (P interaction = 0.55) or related endpoints (all P interaction > 0.20), while 6-minute walk distance was preserved in both strata and KCCQ-OSS improvement appeared attenuated with baseline tafamidis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.